The authors summarized the evidence supporting neuroprotection based on the data available in the literature. In vivo and in vitro studies have indicated that many compounds can decrease neurodegeneration, excitotoxicity, oxidative stress, protein aggregation, disturbance of Ca2+ homeostasis and compensate the energy impairment. Selegiline, rasagiline, dopamine agonists and other molecules (ubiquinone, kynurenic acid, tocopherol, creatine, glatiramer acetate) exert neuroprotective effects in preclinical studies. Much less clinical data are available regarding neuroprotection in different neurological disorders. In this review, such preclinical and clinical evidences are summarized.
|Translated title of the contribution||Neuroprotection in parkinson's disease and other neurodegenerative disorders: Preclinical and clinical findings|
|Number of pages||10|
|Publication status||Published - Jan 30 2009|
ASJC Scopus subject areas
- Clinical Neurology